Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body’s immune system to fight cancer. Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4+ and CD8+ T cells to generate immune response and have the potential to become new targets of tumor immunotherapy.
NSCLC possesses the maximum market share among various Neo-antigen based cancer vaccine indications in the 7 MM countries. While Brain and Bone cancer will occupy the lowest market share in the overall Neoantigen Cancer Vaccine market
Some of the key companies such as OSE Immunotherapeutics, Immunitor, Gristone Oncology, Neon Therapeutics, Genocea, Targovax, Gradalis, are developing drugs for Neoantigen-based Personalized Cancer therapeutic Vaccines.
For more details visit: https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape